All In Biotech

Drug Trial Radar · NCT07158398

Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate

A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Effect of Vimseltinib on BCRP and OATP1B1 Inhibition in Healthy Male Participants

Last checked: Nov 20, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Oct 31, 2025

Primary completion

Dec 8, 2025

Study completion Dec 8, 2025

Sponsor

Lead sponsor
Deciphera Pharmaceuticals, LLCIndustry
Sponsor type
Industry
First posted
Sep 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of this study is to determine the effect of Vimseltinib dosing on breast cancer resistance protein (BCRP) and organic-anion-transporting polypeptide 1 B1 (OAT1PB1) activity by using rosuvastatin in healthy male participants. This study will also evaluate the safety and tolerability when vimseltinib is co-administered with rosuvastatin in healthy male participants. This study will last approximately 26 days.

Conditions

  • Healthy Participants

Interventions

  • VimseltinibDrug

    Administered orally

  • RosuvastatinDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic (PK): Maximum Observed Plasma Drug Concentration (Cmax) of rosuvastatinTime frame: Predose up to 72 hours postdose
  2. PK: Area Under the Concentration Versus Time Curve (AUC) of rosuvastatinTime frame: Predose up to 72 hours postdose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dr. Vince Clinical Research

    Overland Park, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.